|
Cardiovascular Pharmacology
Citations 401-410 of 1154 total displayed.
|
Past content
(since Jan 1999):
|
- Articles
Mitochondrial Ca2+-Activated K+ Channels in Cardiac Myocytes. A Mechanism of the Cardioprotective Effect and Modulation by Protein Kinase A
- Toshiaki Sato, Tomoaki Saito, Noriko Saegusa, and Haruaki Nakaya
Circulation published December 27, 2004, doi:10.1161/01.CIR.0000151099.15706.B1
[Abstract]
- AHA Conference Proceedings
CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: Clinical Use of Inflammatory Markers in Patients With Cardiovascular Diseases: A Background Paper
- Luigi M. Biasucci
Circulation 2004;110:e560-567e, doi:10.1161/01.CIR.0000148983.88334.80
[Abstract]
[Full text]
- AHA Conference Proceedings
CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: Disclosure
-
Circulation 2004;110:e577-578e, doi:10.1161/01.CIR.0000152612.25993.04
[Full text]
- Articles
Cardioprotection by  -Protein Kinase C Activation From Ischemia. Continuous Delivery and Antiarrhythmic Effect of an -Protein Kinase C-Activating Peptide
- Koichi Inagaki, Rebecca Begley, Fumiaki Ikeno, and Daria Mochly-Rosen
Circulation published December 20, 2004, doi:10.1161/01.CIR.0000151614.22282.F1
[Abstract]
- Articles
Role of Omi/HtrA2 in Apoptotic Cell Death After Myocardial Ischemia and Reperfusion
- Hui-Rong Liu, Erhe Gao, Aihua Hu, Ling Tao, Yan Qu, Patrick Most, Walter J. Koch, Theodore A. Christopher, Bernard L. Lopez, Emad S. Alnemri, Antonis S. Zervos, and Xin L. Ma
Circulation published December 20, 2004, doi:10.1161/01.CIR.0000151613.90994.17
[Abstract]
- Editorials
Diabetes, Coronary Intervention, and Platelet Glycoprotein IIb/IIIa Blockade: The Triad Revisited
- W.H. Wilson Tang and A. Michael Lincoff
Circulation 2004;110:3618-3620, doi:10.1161/01.CIR.0000151355.07568.B4
[Full text]
- Late-Breaking Clinical Trials
Placebo-Controlled, Randomized Clinical Trial of Azimilide for Prevention of Ventricular Tachyarrhythmias in Patients With an Implantable Cardioverter Defibrillator
- Paul Dorian, Martin Borggrefe, Hussein R. Al-Khalidi, Stefan H. Hohnloser, Jose M. Brum, Daljit S. Tatla, Johannes Brachmann, Robert J. Myerburg, David S. Cannom, Michael van der Laan, Michael J. Holroyde, Igor Singer, Craig M. Pratt on Behalf of the SHock Inhibition Evaluation with azimiLiDe (SHIELD) Investigators
Circulation 2004;110:3646-3654; published online before print as doi:10.1161/01.CIR.0000149240.98971.A8
[Abstract]
[Full text]
- Heart Failure
Chronic Kidney Disease, Cardiovascular Risk, and Response to Angiotensin-Converting Enzyme Inhibition After Myocardial Infarction: The Survival And Ventricular Enlargement (SAVE) Study
- Mariya P. Tokmakova, Hicham Skali, Satish Kenchaiah, Eugene Braunwald, Jean L. Rouleau, Milton Packer, Glenn M. Chertow, Lemuel A. Moyé, Marc A. Pfeffer, and Scott D. Solomon
Circulation 2004;110:3667-3673; published online before print as doi:10.1161/01.CIR.0000149806.01354.BF
[Abstract]
[Full text]
- Editorials
Atherosclerosis Imaging and the Future of Lipid Management
- Scott M. Grundy
Circulation 2004;110:3509-3511, doi:10.1161/01.CIR.0000151100.28000.B3
[Full text]
- Molecular Cardiology
Control of Plasma Nitric Oxide Bioactivity by Perfluorocarbons: Physiological Mechanisms and Clinical Implications
- Olga Rafikova, Elena Sokolova, Ruslan Rafikov, and Evgeny Nudler
Circulation 2004;110:3573-3580; published online before print as doi:10.1161/01.CIR.0000148782.37563.F8
[Abstract]
[Full text]
|
|
